Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled double-blind trial of citalopram and reboxetine adjunctive to second-generation antipsychotics for negative symptoms of schizophrenia
2007-002838-10Phase 4Completed
- Sponsor
- Sant Joan de Déu Hospital
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of citalopram, reboxetine, risperidone and olanzapine in schizophrenia (3 arms), sponsored by Sant Joan de Déu Hospital. Primary endpoints: Reason for study discontinuation and Efficacy on negative symptoms of schizophrenia. Started Feb 2008; status: completed.
02
Drugs
citalopramreboxetinerisperidoneolanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2007-002838-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002838-10.